4.7 Article

Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma

Journal

Publisher

SPRINGER
DOI: 10.1007/s00259-014-2771-1

Keywords

Malignant melanoma; Sentinel lymph node; SPECT/CT; Cost-effectiveness

Ask authors/readers for more resources

Purpose Malignant melanoma has become a major growing interdisciplinary problem in public health worldwide. Sentinel lymph node excision (SLNE) in conjunction with preoperative SPECT/CT is considered the most sensitive and specific staging test for the detection of micrometastatic melanoma in regional lymph nodes. Among patients with clinically lymph node-negative melanoma, the use of SPECT/CT-aided SLNE compared with SLNE alone has been found to be associated with a higher frequency of metastatic involvement and a higher rate of disease-free survival. The aim of this study was to analyse the cost-effectiveness of SLNE with preoperative SPECT/CT for detecting sentinel lymph nodes versus that of standard SLNE with preoperative lymphoscintigraphy from a single-institution database. Methods Cost-effectiveness analysis of two surgical approaches for SLNE for malignant melanoma at the University Hospital Essen, Skin Cancer Center in Essen, Germany. Between March 2003 and April 2011 464 patients eligible for SLNE were identified . Of these patients, 403 with clinically negative lymph nodes who underwent SLNE with or without preoperative SPECT/CT qualified for subsequent analysis. Results Between March 2003 and October 2008, 254 patients were operated upon with the standard technique. From November 2008, 149 patients underwent the SPECT/CT technique. Cost analysis showed a mean cost saving of a,not sign 710.50 when SPECT/CT was added to preoperative imaging. This was achieved by a reduction in operative time (median, Q1;Q3, 40 min, 40;50 min, vs. 45 min, 35;60 min; p = 0.002), hospital stay duration (5 days, 3;8 days, vs. 8 days, 4.5;14.5 days; p < 0.001) and more frequent use of local anaesthesia (90.6 % vs. 70.5 %; p < 0.001). The median cost of SLNE using SPECT/CT was a,not sign 1,619.7 (Q1;Q3 a,not sign 1,317.0;2,603.4) and of SLNE without SPECT/CT was a,not sign 2,330.2 (a,not sign 1,468.3;4,058.1; p < 0.001), a cost saving of 30.5 %. Conclusion In patients with cutaneous melanoma, the use of preoperative SPECT/CT-aided SLNE compared with standard SLNE was associated not only with higher detection of metastatic involvement but also with a significant cost reduction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Oncology

Immune checkpoint blockade for organ-transplant recipients with cancer: A review

Alessandra Ruenger, Dirk Schadendorf, Axel Hauschild, Christoffer Gebhardt

Summary: Clinical trials studying immune checkpoint inhibitors (ICIs) have excluded immunocompromised patients. This study reviewed the existing literature and analyzed treatment outcomes of 144 patients. The findings suggest that effective immunotherapy with retained transplant was achieved in approximately 30.8% of patients. The overall response rates of immunotherapy were similar to non-immunocompromised cancer patients, but publication bias may overestimate positive outcomes.

EUROPEAN JOURNAL OF CANCER (2022)

Article Oncology

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long

Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Microbiology

Deep Learning Assisted Diagnosis of Onychomycosis on Whole-Slide Images

Philipp Jansen, Adelaida Creosteanu, Viktor Matyas, Amrei Dilling, Ana Pina, Andrea Saggini, Tobias Schimming, Jennifer Landsberg, Birte Burgdorf, Sylvia Giaquinta, Hansgeorg Mueller, Michael Emberger, Christian Rose, Lutz Schmitz, Cyrill Geraud, Dirk Schadendorf, Joerg Schaller, Maximilian Alber, Frederick Klauschen, Klaus G. Griewank

Summary: In this study, a machine learning algorithm was used to detect fungal elements on digitized histologic sections of human nail specimens, and its performance was compared with that of dermatopathologists. The results demonstrated that the algorithm achieved a comparable sensitivity to the human pathologists. This finding suggests that machine learning algorithms can serve as supportive diagnostic tools to improve the screening efficiency of fungal infections.

JOURNAL OF FUNGI (2022)

Article Oncology

Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma

Lucas Schneider, Christoph Wies, Eva I. Krieghoff-Henning, Tabea-Clara Bucher, Jochen S. Utikal, Dirk Schadendorf, Titus J. Brinker

Summary: In this study, the contribution of different data types in a combined classifier for predicting BRAF mutation status in melanoma was analyzed. The multimodal classifier showed improved generalisability compared to individual classifiers.

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma

Alexander C. J. van Akkooi, Dirk Schadendorf, Alexander M. M. Eggermont

Summary: Sentinel lymph node biopsy (SLNB) was introduced in the 1990s to identify patients who may benefit from completion lymph node dissection. SLNB staging has been found to be the best for staging melanoma. Adjuvant systemic therapy and biomarkers are emerging, which might reduce the need for SLNB staging in the future.

EUROPEAN JOURNAL OF CANCER (2023)

Article Dermatology

Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathy

Jan-Malte Placke, Delphine Mertens, Alpaslan Tasdogan, Eleftheria Chorti, Dirk Schadendorf, Selma Ugurel, Alexander Roesch, Ingo Stoffels, Joachim Klode

Summary: This study demonstrates that multispectral optoacoustic tomography (MSOT) can differentiate between benign and malignant lymphadenopathy by measuring the levels of oxyhemoglobin and deoxyhemoglobin in lymph nodes. It offers a noninvasive approach to avoid unnecessary lymph node biopsies and surgeries.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Infectious Diseases

Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general population

Laven Mavarani, Sarah Albayrak-Rena, Anja Potthoff, Martin Hower, Sebastian Dolff, Stefanie Sammet, Felix Maischack, Dirk Schadendorf, Boerge Schmidt, Stefan Esser

Summary: Our study evaluated the changes in weight, body-mass-index (BMI), and waist-to-hip ratio (WHR) over a 5-year follow-up in people living with HIV (PLH) compared to the general population. The results showed that PLH had greater increases in weight and BMI after 5 years, but lower WHR change compared to the general population.

INFECTION (2023)

Article Oncology

Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

Filippo de Braud, Christophe Dooms, Rebecca S. Heist, Celeste Lebbe, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Rutkowski, Juergen Wolf, Paolo A. Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith McKean, Eva Munoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuan-Mai Couillebault, Helen Evans, Catarina D. Campbell, Sumit Basu, Michele Moschetta, Adil Daud

Summary: This study explores a targeted therapy for treating NRAS-mutant melanoma, showing promising antitumor activity in patients with the use of LXH254 and trametinib in combination.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

Paolo Antonio Ascierto, Evan J. Lipson, Reinhard Dummer, James Larkin, Georgina V. Long, Rachel E. Sanborn, Vanna Chiarion-Sileni, Brigitte Dreno, Stephane Dalle, Dirk Schadendorf, Margaret K. Callahan, Marta Nyakas, Victoria Atkinson, Carlos Alberto Gomez-Roca, Naoya Yamazaki, Hussein A. Tawbi, Naomey Sarkis, Deepti Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, Jean-Jacques Grob

Summary: Preliminary research shows that nivolumab and relatlimab have better efficacy in treating advanced melanoma patients who have previously received anti-PD-(L)1 treatment. The RELATIVITY-047 trial demonstrated that nivolumab and relatlimab, compared to nivolumab alone, significantly improved progression-free survival in previously untreated advanced melanoma patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial

Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Jean-Jacques Grob, Andriy Moshyk, Jennifer Lord-Bessen, Melissa Hamilton, Shien Guo, Ling Shi, Sarah Keidel, Georgina Long

Summary: The RELATIVITY-047 trial demonstrates that the fixed-dose combination of nivolumab plus relatlimab improves progression-free survival in patients with advanced melanoma while maintaining stable health-related quality of life. Although the combination treatment is associated with a higher incidence of severe adverse events, patients' discomfort with these events is low, supporting NIVO + RELA as a first-line treatment option.

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

Deep learning detection of melanoma metastases in lymph nodes

Philipp Jansen, Daniel Otero Baguer, Nicole Duschner, Jean Le'Clerc Arrastia, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Joerg Schaller, Klaus Georg Griewank

Summary: In this study, a deep learning method was used to analyze histological tissue sections of melanoma patients, enabling accurate detection of lymph node metastasis and providing valuable reference for pathologists. The method was able to identify the size and classify the tumor, which is of great significance for prognosis assessment and treatment planning.

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma

Carola Berking, Elisabeth Livingstone, Dirk Debus, Carmen Loquai, Michael Weichenthal, Ulrike Leiter, Felix Kiecker, Peter Mohr, Thomas K. Eigentler, Janina Remy, Katharina Schober, Markus V. Heppt, Imke von Wasielewski, Dirk Schadendorf, Ralf Gutzmer

Summary: The outcome of advanced melanoma patients has greatly improved over the past 15 years. Targeted therapies blocking BRAF or inhibiting immune checkpoints have shown significant efficacy in improving overall survival. The COMBI-r study confirms the efficacy of dabrafenib plus trametinib in routine clinical practice and provides additional data in patients with brain metastases or previous treatments.

CANCERS (2023)

Article Oncology

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence

Esmee P. Hoefsmit, Franziska Vollmy, Elisa A. Rozeman, Irene L. M. Reijers, Judith M. Versluis, Liesbeth Hoekman, Alexander C. J. van Akkooi, Georgina Long, Dirk Schadendorf, Reinhard Dummer, Maarten Altelaar, Christian U. Blank

Summary: Taking into account the higher response rates of neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma compared to stage IV disease, researchers hypothesized that systemic immune suppression may be responsible for lower response rates and disease recurrence. Through proteomic profiling, they found that the protein LRG1 is associated with worse prognosis and can serve as a biomarker for identifying high-risk patients and as a potential target for neoadjuvant ICB therapy.

CANCER RESEARCH COMMUNICATIONS (2023)

Article Oncology

Deep learning based histological classification of adnex tumors

Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank

Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

Paolo A. Ascierto, Reinhard Dummer, Helen J. Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T. Flaherty

Summary: The purpose of this study was to evaluate the efficacy and safety of encorafenib alone or in combination with binimetinib for the treatment of advanced BRAF(V600)-mutant melanoma. The results showed that the combination of encorafenib and binimetinib improved progression-free survival and overall response rate, and had better tolerability compared to encorafenib alone.

JOURNAL OF CLINICAL ONCOLOGY (2023)

No Data Available